Adam Kupinski

Adam Kupinski is a highly experienced scientist currently serving as Principal Scientist I at both AbbVie and DJS Antibodies since October 2022 and September 2021, respectively. Previously, Adam held various roles at Ipsen Bioinnovation from April 2016 to September 2021, including Senior Scientist in Protein Sciences and Scientist in Protein Engineering. Adam's research journey includes postdoctoral positions at the University of Leeds and the Center for Regenerative Therapies Dresden, focusing on cancer mechanisms and the Hedgehog signaling pathway. Adam's academic foundation includes a PhD from the International Max Planck Research School for Molecular Cell Biology and Bioengineering, and a Master of Science in Biotechnology from the Intercollegiate Faculty of Biotechnology of the University of Gdańsk and the Medical University of Gdańsk.